Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42 Percent

A personalized mRNA cancer vaccine reduced the risk of aggressive melanoma returning or causing death by 42 percent in a trial of 1,137 high-risk patients, according to results presented this week at the European Society for Medical Oncology Congress in Madrid. The data have been accepted for publication in the New England Journal of Medicine.

The vaccine, developed jointly by Moderna and Merck, uses the same messenger RNA (mRNA, the molecule that instructs cells to build proteins) platform that underpins Moderna's COVID-19 vaccine. Patients who received the vaccine together with Keytruda, Merck's PD-1 inhibitor pembrolizumab, showed markedly better outcomes than those on Keytruda alone.

What did the trial actually show?

The headline figures concern recurrence-free survival, the period after treatment in which patients remain free of cancer relapse.

• 82 percent of patients receiving the vaccine plus Keytruda had no cancer recurrence at two years.
• 70 percent of patients receiving Keytruda alone reached the same mark.
• The combination reduced the cancer's spread to other parts of the body or death by 38 percent.

Researchers are still monitoring participants to determine whether the regimen improves overall survival, a harder endpoint that recurrence data cannot yet replace. That question remains open, and the investigators did not claim an answer.

How does a personalized cancer vaccine work?

Unlike traditional vaccines, which aim to prevent disease in healthy people, this construct is a therapeutic vaccine built for one patient's tumor. Scientists sequence the mutations in a surgically removed melanoma, then manufacture an mRNA vaccine that instructs the patient's immune system to recognize and destroy cells carrying those specific mutations.

Keytruda is not a bystander in the scheme. The immunotherapy works by releasing a brake on the body's immune cells, allowing them to kill cancer more effectively; the vaccine is designed to point that activated immune response at the patient's tumor signatures.

The comparison worth holding onto: recurrence-free survival improved by 12 percentage points at two years, 82 percent against 70 percent. That absolute gap, not the relative 42 percent figure, is what a patient would weigh.

Is the vaccine available now?

No. The treatment remains experimental and has not been approved by any regulator. Manufacturer enthusiasm about a "new treatment paradigm" should be read against that status; the results, while substantial, come from trial conditions rather than routine clinical use.

What the released results do not yet include is a survival benefit. Until overall survival data mature, the case for the combination rests on recurrence and metastasis endpoints alone.

What comes next?

The findings could pave the way for personalized vaccines against other malignancies, including lung, kidney and pancreatic tumors. If the approach validates across those cancers, dermatology's stake is foundational: melanoma, the deadliest form of skin cancer, would become the proof-of-concept indication for an entire class of individualized oncology therapeutics.

For now, the field awaits survival data and regulatory review before the 42 percent figure moves from congress presentation to approved therapy.